Healthcare M&A » By The Online Investor Staff, updated Sat., Jan. 23, 5:44 AM
Recent mergers and acquisitions in the Healthcare M&A category.
| This Slide: #53 of 100 |
Slide #53. Charles River Laboratories — CRO Services Division of Galapagos NV
Acquirer:
Charles River Laboratories (NYSE:CRL)
Acquiree:
CRO Services Division of Galapagos NV
Details:
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it has completed the previously announced acquisition of the CRO services division of Galapagos NV (Euronext: GLPG), which includes both Argenta and BioFocus. The acquisition positions Charles River as a full service, early-stage contract research organization (CRO), with integrated in vitro and in vivo capabilities from target discovery through preclinical development.
Charles River Laboratories International is a contract research organization. Co. has a laboratory animal medicine and science to develop a portfolio of discovery and safety assessment services. Co.'s segments are: Research Models and Services, which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides DSA services, including in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development; and Manufacturing Support, which ensures the production and release of products manufactured by Co.'s clients.
CRL SEC Filing Email Alerts Service
Open the CRL Page at The Online Investor »
|
|||||||||||||||||||||
Open the CRL Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
 
|
Strong Buy (3.65 out of 4) 67th percentile
(ranked higher than approx. 67% of all stocks covered)
Analysts' Target Price: CRL Stock Forecast Based on Zacks ABR data; powered by Xignite |
